Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate–amodiaquine fixed dose combination or artemether–lumefantrine in Liberia

[1]  S. Abdulla,et al.  The effect of dose on the antimalarial efficacy of artemether – lumefantrine : a systematic review and pooled analysis of individual patient data Worldwide Antimalarial Resistance Network ( WWARN ) AL Dose Impact Study Group , 2015 .

[2]  Badria B. El-Sayed,et al.  Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine , 2014, The American journal of tropical medicine and hygiene.

[3]  P. Rosenthal,et al.  Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. , 2014, The American journal of tropical medicine and hygiene.

[4]  F. Nosten,et al.  Single nucleotide polymorphisms in Plasmodium falciparum V type H(+) pyrophosphatase gene (pfvp2) and their associations with pfcrt and pfmdr1 polymorphisms. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[5]  J. Le bras,et al.  Plasmodium falciparum Polymorphisms Associated with Ex Vivo Drug Susceptibility and Clinical Effectiveness of Artemisinin-Based Combination Therapies in Benin , 2013, Antimicrobial Agents and Chemotherapy.

[6]  E. Ashley,et al.  Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial , 2013, Malaria Journal.

[7]  M. Petzold,et al.  Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania , 2013, Malaria Journal.

[8]  Andreas Mårtensson,et al.  Plasmodium falciparum Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association With pfmdr1 Polymorphisms , 2012, The Journal of infectious diseases.

[9]  M. Msellem,et al.  Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar , 2012, Malaria Journal.

[10]  A. Dicko,et al.  Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. , 2008, The American journal of tropical medicine and hygiene.

[11]  A. Mårtensson,et al.  Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[12]  S. Krishna,et al.  The role of pfmdr1 in Plasmodium falciparum tolerance to artemether‐lumefantrine in Africa , 2007, Tropical medicine & international health : TM & IH.

[13]  P. Rosenthal,et al.  Selection of Plasmodium falciparum pfmdr1 Alleles following Therapy with Artemether-Lumefantrine in an Area of Uganda where Malaria Is Highly Endemic , 2006, Antimicrobial Agents and Chemotherapy.

[14]  F. Checchi,et al.  High Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine in Harper, Liberia: results in vivo and analysis of point mutations. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.